Changes of Plasma Lipids by the Administration of Halofenate-double Blind Trial
Ichiro Takeuchi(National Center For Child Health and Development), Yuichiro Goto(Tokai University), Yoichi Umetada(Sumitomo Mitsui Banking Corporation), Noboru IRIE(Kurashiki Central Hospital), Yasuteru Tonomo(Keio University Hospital), Yutaka Hata(University of Hyogo), Takahito Hara(Takeda (Japan)), H. Nakamura(Keio University Hospital), T. ISHIKAWA(Keio University Hospital), Yoshiharu Ehata(Fuji Electric (Japan)), Hiroshi Shigematsu(Keio University Hospital), Motoo Tsushima(National Cerebral and Cardiovascular Center)
Cited by 0
Related Papers
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
|PubMed|2003|427
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
|Proceedings of the National Academy of Sciences|2018|172
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
|Bioorganic & Medicinal Chemistry|2011|126
JCS 2017 Guideline on Management of Vasculitis Syndrome ― Digest Version ―
|Circulation Journal|2020|121